Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Adaptimmune Therapeutics plc is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptimmune Therapeutics employs 420 staff and has a trailing 12-month revenue of around USD$3.2 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$2 - USD$12.48 |
---|---|
50-day moving average | USD$6.0109 |
200-day moving average | USD$6.4356 |
Wall St. target price | USD$11.33 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.967 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Adaptimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Revenue TTM | USD$3.2 million |
---|---|
Gross profit TTM | USD$-96,379,000 |
Return on assets TTM | -22.96% |
Return on equity TTM | -46.9% |
Profit margin | 0% |
Book value | $2.431 |
Market capitalisation | USD$920.9 million |
TTM: trailing 12 months
There are currently 1.4 million Adaptimmune Therapeutics shares held short by investors – that's known as Adaptimmune Therapeutics's "short interest". This figure is 8.1% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Adaptimmune Therapeutics shares can be evaluated.
Adaptimmune Therapeutics's "short interest ratio" (SIR) is the quantity of Adaptimmune Therapeutics shares currently shorted divided by the average quantity of Adaptimmune Therapeutics shares traded daily (recently around 1.3 million). Adaptimmune Therapeutics's SIR currently stands at 1.11. In other words for every 100,000 Adaptimmune Therapeutics shares traded daily on the market, roughly 1110 shares are currently held short.
However Adaptimmune Therapeutics's short interest can also be evaluated against the total number of Adaptimmune Therapeutics shares, or, against the total number of tradable Adaptimmune Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptimmune Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Adaptimmune Therapeutics shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Adaptimmune Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptimmune Therapeutics.
Find out more about how you can short Adaptimmune Therapeutics stock.
We're not expecting Adaptimmune Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $2 up to $12.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 2.215. This would suggest that Adaptimmune Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.